8-K current report · filed Aug 5, 2026

biote Corp. (BTMD) 8-K Current Report: August 5, 2026

Item EX-99.1Item 2.02BTMD overview

Short answer

biote Corp. (BTMD) filed an 8-K current report with the SEC on August 5, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Biote reported financial results for Q2 ended June 30, 2026.

biote Corp. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Biote reported financial results for Q2 ended June 30, 2026
  • Press release dated August 5, 2026 contains the substantive earnings details
  • Investors should review Exhibit 99.1 for revenue, profitability, guidance and operating metrics

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue fell 9.5% to $44.2M, with procedure revenue down 13.9% to $30.3M from the January 2026 voluntary recall
  • Gross margin contracted to 65.4% from 71.6% due to higher replacement-product costs and reduced Asteria Health manufacturing efficiency
  • Net loss reached $7.4M, or $(0.23) per diluted share, versus $3.9M net income and $0.10 EPS in Q2 2025
  • Adjusted EBITDA declined to $5.6M from $15.2M, while margin fell to 12.6% from 31.1%
  • Full-year guidance now calls for revenue above $175M and Adjusted EBITDA above $25M, with procedure revenue growth delayed beyond 2026 second-half periods

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other biote Corp. 8-K filings

Get the next BTMD 8-K as it lands

Follow BTMD for push alerts, or ask the research agent what this filing means.